The Business Behind...
Health Care: Drugs
Delcath Systems Inc. (DCTH: NASDAQ)
$0.44 0.00 | -0.90%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 23.73M | 25.78M | 45.62M | 35.49M |
| Receivables | 144.00K | 0.00 | 0.00 | 0.00 |
| Inventories | 1.10M | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 26.43M | 31.99M | 48.90M | 36.29M |
| Property, Plant & Equipment, Gross | 6.88M | 4.76M | 2.16M | 546.29K |
| Accumulated Depreciation & Depletion | 2.84M | 1.51M | 477.42K | 24.98K |
| Property, Plant & Equipment, Net | 4.04M | 3.25M | 1.68M | 521.31K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 4.04M | 3.25M | 1.68M | 521.31K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 30.47M | 35.24M | 50.58M | 36.81M |
| Accounts Payable | 939.00K | 925.00K | 610.46K | 1.84M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 3.43M | 2.44M | 18.01M | 11.21M |
| Total Current Liabilities | 10.16M | 8.84M | 21.20M | 13.05M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 309.00K | 300.00K | 300.00K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 309.00K | 300.00K | 300.00K | 0.00 |
| Total Liabilities | 10.46M | 9.14M | 21.50M | 13.05M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 20.01M | 26.10M | 29.08M | 23.76M |
| Common Par | 768.00K | 482.00K | 430.28K | 362.23K |
| Additional Paid In Capital | 218.06M | 172.61M | 144.78M | 92.84M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -198.81M | -146.94M | -116.06M | -69.37M |
| Treasury Stock | -51.00K | -51.00K | -51.10K | -51.10K |
| Other Equity Adjustments | 37.00K | 0.00 | -26.20K | -16.20K |
| Total Capitalization | 20.01M | 26.10M | 29.08M | 23.76M |
| Total Equity | 20.01M | 26.10M | 29.08M | 23.76M |
| Total Liabilities & Stock Equity | 30.47M | 35.24M | 50.58M | 36.81M |
| Total Common Shares Outstanding | 76.82M | 48.02M | 42.93M | 36.19M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 28.10K | 28.10K | 28.10K | 28.10K |
| Basic Weighted Shares Outstanding | 61.28M | 45.24M | 38.99M | 27.07M |
| Diluted Weighted Shares Outstanding | 61.28M | 45.24M | 38.99M | 27.07M |
| Number of Employees | 92 | 80 | 47 | 17 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with DCTH
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserMy Portfolio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserROSIE
Latest DCTH Headlines from TheStreet
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- Stock Futures Eye Rebound on ECB Stimulus, U.S. Data 05.02.13 | 08:05 am
- Aveo, Delcath FDA Panel Live Blog 05.02.13 | 07:05 am
- FDA Tells Delcath No Approval Without New Clinical Trial 04.30.13 | 10:04 am
- Prepping for Aveo, Delcath FDA Panels 04.29.13 | 02:04 pm
- Biotech's Next Big Thing: Aveo
04.25.13 | 09:04 am - Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm 03.15.13 | 06:03 am
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
Press Releases for DCTH
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Delcath Systems, Inc. To Contact The Firm - PR Newswire 05.18.13 | 09:05 am
- Delcath Systems, Inc. Sued By Investor - PR Newswire 05.10.13 | 07:05 pm
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Delcath Systems, Inc. - PR Newswire 05.03.13 | 08:05 am
- Delcath To Present At JMP Securities Healthcare Conference On July 12 - PR Newswire 07.09.12 | 04:07 pm
- Delcath Announces First CHEMOSAT Procedures In Germany - PR Newswire 02.27.12 | 06:02 am
- Delcath Announces Updated Efficacy Results From Phase 3 Trial Of Chemosaturation For Melanoma Metastases In The Liver Presented At European Multidisciplinary Cancer Congress - PR Newswire 09.23.11 | 06:09 pm
- Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE - PR Newswire 09.13.11 | 02:09 am
- Delcath Systems Receives Refusal To File Letter From FDA - PR Newswire 02.22.11 | 05:02 am
- Delcath Achieves ISO 13485 Certification - PR Newswire 02.17.11 | 09:02 am
- Delcath Completes New Drug Application Submission To The FDA For The Chemosaturation Delivery System - PR Newswire 12.22.10 | 07:12 am
Partner Headlines for DCTH
- Is Delcath The Post-Celsion Play On Liver Cancer? - Seeking Alpha 02.04.13 | 09:02 am
- Morning Market Losers - Benzinga 10.15.12 | 09:10 am
- Benzinga's Microcap Movers for Friday October 5, 2012 - Benzinga 10.06.12 | 06:10 pm
- Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst - Seeking Alpha 09.28.12 | 09:09 am
- Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO - GuruFocus 06.11.12 | 01:06 pm
- Active Stock Alerts: Dendreon, Delcath Systems, Johnson & Johnson, Boeing, Onyx June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Hyper-Novel Investments For Targeting Cancer - Seeking Alpha 05.30.12 | 09:05 am
- Mid-Day Update: Stocks Trending Water Ahead of First Holiday Weekend of Summer - NASDAQ 05.25.12 | 04:05 pm
- Mid-Day Market Losers - Benzinga 05.25.12 | 01:05 pm
- 4 Stocks Attracting Heavy Trading Interest - Wall St. Cheat Sheet 05.25.12 | 12:05 pm
